ALKEM LABORATORIES Financial Statement Analysis
|
||
The Revenues of ALKEM LABORATORIES have increased by 2.34% YoY .
The Earnings Per Share (EPS) of ALKEM LABORATORIES has increased by 20.59 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
ALKEM LABORATORIES Last 5 Annual Financial Results
[BOM: 539523|NSE : ALKEM]
Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
---|---|---|---|---|---|
Revenues | ₹12,965 Cr | ₹12,668 Cr | ₹11,599 Cr | ₹10,634 Cr | ₹8,865 Cr |
Expenses | ₹10,452 Cr | ₹10,422 Cr | ₹9,990 Cr | ₹8,581 Cr | ₹6,923 Cr |
Operating Profit (Excl OI) | ₹2,512 Cr | ₹2,245 Cr | ₹1,609 Cr | ₹2,053 Cr | ₹1,942 Cr |
Other Income | ₹494 Cr | ₹311 Cr | ₹216 Cr | ₹163 Cr | ₹233 Cr |
Interest | ₹122 Cr | ₹112 Cr | ₹107 Cr | ₹52 Cr | ₹59 Cr |
Depreciation | ₹357 Cr | ₹299 Cr | ₹310 Cr | ₹304 Cr | ₹275 Cr |
Profit Before Tax | ₹2,527 Cr | ₹2,023 Cr | ₹1,305 Cr | ₹1,844 Cr | ₹1,842 Cr |
Profit After Tax | ₹2,216 Cr | ₹1,811 Cr | ₹1,007 Cr | ₹1,680 Cr | ₹1,618 Cr |
Consolidated Net Profit | ₹2,165 Cr | ₹1,796 Cr | ₹984 Cr | ₹1,646 Cr | ₹1,585 Cr |
Earnings Per Share (Rs) | ₹181.14 | ₹150.21 | ₹82.32 | ₹137.65 | ₹132.58 |
PAT Margin (%) | 11.48 | 9.35 | 5.61 | 11.00 | 12.34 |
ROE(%) | 19.93 | 18.74 | 11.39 | 20.99 | 23.91 |
ROCE(%) | 21.56 | 19.52 | 13.09 | 18.69 | 22.56 |
Total Debt/Equity(x) | 0.09 | 0.12 | 0.14 | 0.30 | 0.23 |
Key Financials |
||
Market Cap | : | ₹ 58,541.8 Cr |
Revenue (TTM) | : | ₹ 12,964.5 Cr |
Net Profit(TTM) | : | ₹ 2,216.0 Cr |
EPS (TTM) | : | ₹ 185.3 |
P/E (TTM) | : | 26.4 |
Industry Peers & Returns | 1W | 1M | 1Y |
ALKEM LABORATORIES | -3% | 1.6% | -5.3% |
SUN PHARMACEUTICAL INDUSTRIES | -4.3% | -3% | -0.7% |
DIVIS LABORATORIES | -3.3% | -7.4% | 34.1% |
CIPLA | -4.4% | -0.5% | 0.7% |
TORRENT PHARMACEUTICALS | 1.4% | 10.1% | 17.9% |
DR REDDYS LABORATORIES | -5.2% | -5.7% | -5.9% |
MANKIND PHARMA | 0.8% | 8.4% | 26.4% |
ZYDUS LIFESCIENCES | -3.1% | -5.1% | -22.2% |
LUPIN | -4.9% | -4.6% | 0.9% |
ALKEM LABORATORIES Revenues
[BOM: 539523|NSE : ALKEM]
Y-o-Y | 2.34 % |
5 Yr CAGR | 9.97 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2025 | ₹12,965 Cr | 2.34 | |
Mar2024 | ₹12,668 Cr | 9.21 | |
Mar2023 | ₹11,599 Cr | 9.08 | |
Mar2022 | ₹10,634 Cr | 19.96 | |
Mar2021 | ₹8,865 Cr | - |
ALKEM LABORATORIES Operating Profit
[BOM: 539523|NSE : ALKEM]
Y-o-Y | 11.88 % |
5 Yr CAGR | 6.64 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2025 | ₹2,512 Cr | 11.88 | |
Mar2024 | ₹2,245 Cr | 39.52 | |
Mar2023 | ₹1,609 Cr | -21.60 | |
Mar2022 | ₹2,053 Cr | 5.69 | |
Mar2021 | ₹1,942 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | 9.31 % |
5 Yr CAGR | -3.02 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2025 | 19.38% | 9.31 | |
Mar2024 | 17.73% | 27.74 | |
Mar2023 | 13.88% | -28.08 | |
Mar2022 | 19.3% | -11.91 | |
Mar2021 | 21.91% | - |
ALKEM LABORATORIES Profit After Tax
[BOM: 539523|NSE : ALKEM]
Y-o-Y | 20.59 % |
5 Yr CAGR | 8.11 % |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2025 | ₹2,165 Cr | 20.59 | |
Mar2024 | ₹1,796 Cr | 82.47 | |
Mar2023 | ₹984 Cr | -40.19 | |
Mar2022 | ₹1,646 Cr | 3.82 | |
Mar2021 | ₹1,585 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | 22.78 % |
5 Yr CAGR | -1.79 % |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2025 | 11.48 % | 22.78 | |
Mar2024 | 9.35 % | 66.67 | |
Mar2023 | 5.61 % | -49.00 | |
Mar2022 | 11 % | -10.86 | |
Mar2021 | 12.34 % | - |
ALKEM LABORATORIES Earnings Per Share (EPS)
[BOM: 539523|NSE : ALKEM]
Y-o-Y | 20.59 % |
5 Yr CAGR | 8.11 % |
Years | EPS | % Change | |
---|---|---|---|
Mar2025 | ₹181 | 20.59 | |
Mar2024 | ₹150 | 82.47 | |
Mar2023 | ₹82 | -40.20 | |
Mar2022 | ₹138 | 3.82 | |
Mar2021 | ₹133 | - |
ALKEM LABORATORIES Return on Capital Employed (ROCE)
[BOM: 539523|NSE : ALKEM]
Y-o-Y | 10.45 % |
5 Yr CAGR | -1.13 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2025 | 21.56% | 10.45 | |
Mar2024 | 19.52% | 49.12 | |
Mar2023 | 13.09% | -29.96 | |
Mar2022 | 18.69% | -17.15 | |
Mar2021 | 22.56% | - |
ALKEM LABORATORIES Share Price vs Sensex
Current Share Price | : | ₹4,894.8 |
Current MarketCap | : | ₹ 58,541.8 Cr |
Updated EOD on | : | Aug 01,2025 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
ALKEM LABORATORIES | -3% |
1.6% |
-5.3% |
SENSEX | -1.1% |
-3.4% |
-1.1% |
ALKEM LABORATORIES related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
BSE ALLCAP | 6.4% | 8.9% | 7.5% |
BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
BSE LARGEMIDCAP | 4.5% | 7.2% | 8.3% |
BSE 500 SHARIAH | 4.3% | 4.3% | 1.1% |
BSE 200 | -1.3% | -3.7% | -3.4% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY ALPHA QUALITY VALUE LOW-VOLATILITY 30 | -0.4% | -2.1% | -9.2% |
NIFTY MIDCAP150 QUALITY 50 | -0.9% | -3.1% | -4.9% |
NIFTY 200 | -1.4% | -3.8% | -3% |
NIFTY 500 | -1.5% | -3.7% | -3.3% |
NIFTY TOTAL MARKET | -1.5% | -3.7% | -3.3% |
You may also like the below Video Courses
FAQ about ALKEM LABORATORIES Financials
How the annual revenues of ALKEM LABORATORIES have changed ?
The Revenues of ALKEM LABORATORIES have increased by 2.34% YoY .
How the Earnings per Share (EPS) of ALKEM LABORATORIES have changed?
The Earnings Per Share (EPS) of ALKEM LABORATORIES has increased by 20.59 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs